Skip to main content

Bank of England acts to keep banks lending through 2021

https://foundflight.com/cities/london/ LONDON (Reuters) -The Bank of England took steps on Friday to keep banks lending through 2021 as Britain deals with the COVID pandemic and a big change in its trading relationship with the European Union.

The central bank said the counter-cyclical capital buffer will be kept at zero until at least the last quarter of 2021 - extra money banks must set aside during economic good times.

There is no need for banks to introduce any potential changes before the end of 2022.

"Some headwinds to the capital ratios of banks are... The BoE said in a half-yearly assessment of the health of the financial system that it anticipated that unemployment will rise over the coming quarters, business insolvencies will rise from current low levels, and risk weights will increase on bank exposures.

"The United Kingdom's major banks, however can absorb credit losses in the order of 200 billion pounds, much more than would be implied if the economy followed a path consistent with the central forecast of the Monetary Policy Committee," it added.

The BoE also reiterated that after a post-Brexit adjustment phase ending on Jan. 1, it did not intend to loosen financial standards.

"Regardless of the basic shape of the UK's potential relationship with the EU,... The Financial Policy Committee remains committed to the introduction in the United Kingdom of robust prudential principles.

Comments

Post a Comment

Popular posts from this blog

The CEO of AstraZeneca plans to conduct the latest global COVID-19 vaccine trial: Bloomberg

(Reuters) - An additional global trial to test the effectiveness of its COVID-19 vaccine using a lower dose is likely to be conducted by AstraZeneca, its chief executive was quoted as saying on Thursday amid concerns about the outcome of its late-stage review. AstraZeneca could start a new study to test a lower dose of its vaccine that worked better than a full dosage, Pascal Soriot told Bloomberg News, instead of adding the trial to an existing U.S. phase. "We have to validate this now that we have discovered what looks like a better efficacy, so we need to do an additional study," he said, adding that the latest, likely global, study could be quicker because it would require less subjects as the effectiveness was already established to be high. The news comes as AstraZeneca faces concerns about its success rate that some analysts claim could impede its chances of securing rapid regulatory approval from the U.S. and EU. Several scientists have raised concerns about the r
Post a Comment
Read more

In 'challenging point' Brexit trade negotiations, British minister says

LONDON (Reuters) - Brexit trade negotiations are in a difficult process, and only if the European Union understands that Britain is a sovereign nation will an agreement be reached, said Business Secretary Alok Sharma. "We're at a critical stage," Sky TV told Sharma. "It is fair to say that we are in a difficult phase, that there are still some difficult problems to solve." "We have always said right from the beginning of this process that only if the EU recognizes that the UK is a sovereign independent nation can an agreement be reached," Sharma said. "It is on the basis of that a deal will be done."
Post a Comment
Read more

AstraZeneca to purchase Alexion to grow in immunology for $39 billion

FRANKFURT (Reuters) -Britain's AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals in the biggest transaction ever for $39 billion, diversifying its fast-growing cancer sector in a gamble on medicines for rare diseases and immunology. The deal comes a week after AstraZeneca said it was undertaking more testing to confirm whether its COVID-19 vaccine could be 90% successful, potentially delaying its introduction, and was introduced in Britain as a competing shot from Pfizer and approved for use in the United States . On Saturday, the British company said Alexion shareholders will receive $60 in cash and around $115 worth of equity per share - either in ordinary shares exchanged in the UK by AstraZeneca or in American Depositary Shares denominated in dollars. That implies a total price of $175 per share based on a reference average ADR price of $54.14. Alexion shares closed on Friday at about $121 apiece. "It's a tremendous opportunity for us to accelera
Post a Comment
Read more